ATC Group: V03AC03 Deferasirox

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V03AC03 in the ATC hierarchy

Level Code Title
1 V Various
2 V03 All other therapeutic products
3 V03A All other therapeutic products
4 V03AC Iron chelating agents
5 V03AC03 Deferasirox

Active ingredients in V03AC03

Active Ingredient

Deferasirox is an orally active chelator that is highly selective for iron (III). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces.

Related product monographs

Document Type Information Source  
 EXJADE Dispersible tablet MPI, EU: SmPC European Medicines Agency (EU)
 EXJADE Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 EXJADE Granules in sachet MPI, EU: SmPC European Medicines Agency (EU)
 JADENU Film-coated tablet / Granules MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicines in this ATC group

United States (US)

Albania (AL)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.